Trade the "Maybes" at your peril

I am in New York this week to see clients and prospects, which is why I haven't yet had time to say much about Mr. Trump snatching the prize or the crazy market moves that have followed. I don't see much change . The espresso in Murray Hill, served by Chinese immigrations, is exquisite as ever and New Yorkers remain notoriously impatient, and bad, drivers. I do notice a big increase in TV-ads for Range Rover and Jaguar, though, so maybe there is a concrete sign of the alleged rapprochement between the U.S. and the U.K. in the aftermath of Brexit and Mr. Trump's victory. 

Read More
Equities Finally Get the Memo

After a week's break, and a detour, I am back in the saddle for a busy run-in to Christmas. The main market mover of note, while trawling the museums and bars of Paris, was that global equities finally showed a bit of weakness. The MSCI World slid 1.8% last week, down 4.8% from its peak in August, which means that the index is flat as a pancake year-to-date. A belated reaction to the recent mini tantrum in bond markets, or a knee-jerk reaction to tighter polls across the pond, are probably the lazy strategist's reason for the sell off. But it has been coming regardless. 

Read More
Fancy a Detour?

Your blogger is on holiday this week, so there will be no market musings until next week. In any case, no one wants to talk about anything other than the U.S. elections anyway, and I have preciously little to add on that topic. If you want respite from the tedious mudslinging in U.S. politics, however, read on. 

My latest short story is finally done, and I am offering it to you free of charge

Read More
The old maid of Q3 earnings

In equities, the headline indices were largely directionless last but there was a lot of action underneath the surface thanks to firms in the U.S. report Q3 earnings. On that note, the season has so far been unkind to your humble scribe; indeed it seems that I have managed to get myself stuck with nothing other than the old maid this quarter. There can be no better way to re-introduce the Mark to Market section than to report how yours truly was in front of the queue at the proctologist last week. The portfolio was thoroughly rear-ended by the calamity of Syntel Inc earnings. 

Read More